Organogenesis Holdings Inc. (ORGO) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2025
Loading P/E history...
ORGO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Organogenesis Holdings Inc. (ORGO) trades at a price-to-earnings ratio of 16.7x, with a stock price of $2.51 and trailing twelve-month earnings per share of $-0.00.
The current P/E is 54% below its 5-year average of 36.7x. Over the past five years, ORGO's P/E has ranged from a low of 7.1x to a high of 111.1x, placing the current valuation at the 27th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ORGO trades at a 25% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ORGO trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ORGO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ORGO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $548M | 11.5Lowest | - | +14%Best | |
| $787M | 14.5 | 0.43Best | -35% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ORGO Historical P/E Data (2020–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $5.18 | $0.11 | 45.5x | +24% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $2.84 | $0.04 | 65.3x | +78% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $4.09 | $0.04 | 111.1x | +203% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $3.18 | $0.10 | 32.5x | -12% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $3.32 | $0.08 | 43.8x | +19% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $2.13 | $0.10 | 20.9x | -43% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $2.69 | $0.13 | 21.5x | -41% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $3.24 | $0.46 | 7.1x | -81% |
| FY2022 Q2 | $4.88 | $0.55 | 8.9x | -76% | |
| FY2022 Q1 | $7.62 | $0.63 | 12.1x | -67% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $9.24 | $0.70 | 13.2x | -64% |
| FY2021 Q3 | $14.24 | $0.46 | 31.0x | -16% |
Average P/E for displayed period: 36.7x
See ORGO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ORGO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ORGO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonORGO — Frequently Asked Questions
Quick answers to the most common questions about buying ORGO stock.
Is ORGO stock overvalued or undervalued?
ORGO trades at 16.7x P/E, below its 5-year average of 36.7x. At the 27th percentile of historical range, the stock is priced at a discount to its own history.
How does ORGO's valuation compare to peers?
Organogenesis Holdings Inc. P/E of 16.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ORGO's PEG ratio?
ORGO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2025.